Literature DB >> 15962233

Lack of association between New Haven coronavirus and Kawasaki disease.

Takashi Ebihara, Rika Endo, Xiaoming Ma, Nobuhisa Ishiguro, Hideaki Kikuta.   

Abstract

Entities:  

Mesh:

Year:  2005        PMID: 15962233      PMCID: PMC7197937          DOI: 10.1086/430797

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


× No keyword cloud information.
To the Editor—The new human coronavirus NL63 (HCoV-NL63) was discovered by van der Hoek et al. [1] and Fouchier et al. [2]. HCoV-NL63 has been shown to cause respiratory tract disease in young children [3, 4]. Esper et al. have reported a novel HCoV designated the “New Haven coronavirus” (HCoV-NH) that has been shown by sequence analysis to be very similar to HCoV-NL63 [5]. Esper et al. also reported that HCoV-NH was detected by reverse-transcription polymerase chain reaction (RT-PCR) in 8 (72.7%) of 11 respiratory tract samples from children with Kawasaki disease (KD) and in 1 (4.5%) of 22 age-matched samples from control subjects [6]. On the basis of these data, they suggested that HCoV-NH infection was associated with KD. To further investigate whether HCoV-NH disease is associated with KD, we performed a retrospective study From October 2002 to May 2003, 19 nasopharyngeal swab samples were collected from 19 children who fulfilled the criteria for KD and who were treated at Tenshi Hospital in Sapporo, Japan. All of the samples were collected after informed consent was obtained from the children’s parents. All of the samples were obtained within 7 days of the onset of illness. The mean age of the children with KD was 22.6 months (range, 4 months–5 years). We used as controls 208 nasopharyngeal swab samples that were collected from children with diagnoses of respiratory tract disease who were admitted to hospitals in Sapporo, Japan, during the same period. All of these samples were examined after the possibility of infection with human respiratory syncytial virus or influenza A or B was excluded by rapid antigen-detection tests. The mean age of the children with respiratory tract disease was 21.6 months (range, 4 months–5 years). After extraction of total RNA and synthesis of cDNA, we performed RT-PCR to detect the HCoV-NH genome, as described by Esper et al. [6]. The primer set and the PCR conditions in our PCR assay were the same as those used in their PCR assays. Sequencing of the PCR products was also performed to confirm the presence of HCoV-NH Although RNA sequences of HCoV-NH were detected in samples from 5 (2.4%) of the 208 control children with respiratory tract disease, we could not detect any RNA sequences of HCoV-NH in 19 samples from children with KD (table 1). On the basis of these data, we have some reservations about the findings described by Esper et al. [6]. They collected respiratory tract swab samples from children with KD as part of an ongoing epidemiological investigation of respiratory tract viruses. We collected respiratory tract swab samples from all of the patients with KD, regardless of the presence of respiratory tract symptoms, who were treated at Tenshi Hospital from October 2002 to May 2003. Because no RNA sequences of HCoV-NH were detected in samples from 19 patients with KD in our study, there is a possibility that Esper et al. tested samples from patients with KD who had respiratory tract symptoms. Our results suggest that Esper et al.’s results may be coincidental and that HCoV-NH does not play a dominant role in the etiology or pathogenesis of KD in Japan
Table 1

Detection of New Haven coronavirus (HCoV-NH) in children with Kawasaki disease (KD) and in children with respiratory tract disease (RTDs)

Detection of New Haven coronavirus (HCoV-NH) in children with Kawasaki disease (KD) and in children with respiratory tract disease (RTDs)
  6 in total

1.  A previously undescribed coronavirus associated with respiratory disease in humans.

Authors:  Ron A M Fouchier; Nico G Hartwig; Theo M Bestebroer; Berend Niemeyer; Jan C de Jong; James H Simon; Albert D M E Osterhaus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-08       Impact factor: 11.205

2.  Evidence of a novel human coronavirus that is associated with respiratory tract disease in infants and young children.

Authors:  Frank Esper; Carla Weibel; David Ferguson; Marie L Landry; Jeffrey S Kahn
Journal:  J Infect Dis       Date:  2005-01-14       Impact factor: 5.226

3.  New human coronavirus, HCoV-NL63, associated with severe lower respiratory tract disease in Australia.

Authors:  Katherine E Arden; Michael D Nissen; Theo P Sloots; Ian M Mackay
Journal:  J Med Virol       Date:  2005-03       Impact factor: 2.327

4.  Association between a novel human coronavirus and Kawasaki disease.

Authors:  Frank Esper; Eugene D Shapiro; Carla Weibel; David Ferguson; Marie L Landry; Jeffrey S Kahn
Journal:  J Infect Dis       Date:  2005-01-14       Impact factor: 5.226

5.  Detection of human coronavirus NL63 in young children with bronchiolitis.

Authors:  Takashi Ebihara; Rika Endo; Xiaoming Ma; Nobuhisa Ishiguro; Hideaki Kikuta
Journal:  J Med Virol       Date:  2005-03       Impact factor: 2.327

6.  Identification of a new human coronavirus.

Authors:  Lia van der Hoek; Krzysztof Pyrc; Maarten F Jebbink; Wilma Vermeulen-Oost; Ron J M Berkhout; Katja C Wolthers; Pauline M E Wertheim-van Dillen; Jos Kaandorp; Joke Spaargaren; Ben Berkhout
Journal:  Nat Med       Date:  2004-03-21       Impact factor: 53.440

  6 in total
  33 in total

Review 1.  The novel human coronaviruses NL63 and HKU1.

Authors:  Krzysztof Pyrc; Ben Berkhout; Lia van der Hoek
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

2.  Inhibition of human coronavirus NL63 infection at early stages of the replication cycle.

Authors:  Krzysztof Pyrc; Berend Jan Bosch; Ben Berkhout; Maarten F Jebbink; Ronald Dijkman; Peter Rottier; Lia van der Hoek
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Lack of association between ORAI1/CRACM1 gene polymorphisms and Kawasaki disease in the Taiwanese children.

Authors:  Ho-Chang Kuo; Ying-Jui Lin; Suh-Hang Hank Juo; Yu-Wen Hsu; Wei-Chiao Chen; Kuender D Yang; Chi-Di Liang; Shengyu Yang; Mei-Chyn Chao; Hong-Ren Yu; Shouyan Wang; Li-Yan Lin; Wei-Chiao Chang
Journal:  J Clin Immunol       Date:  2011-04-13       Impact factor: 8.317

Review 4.  Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus.

Authors:  Susan R Weiss; Sonia Navas-Martin
Journal:  Microbiol Mol Biol Rev       Date:  2005-12       Impact factor: 11.056

5.  Human coronavirus-NL63 infection is not associated with acute Kawasaki disease.

Authors:  S C Baker; C Shimizu; H Shike; F Garcia; L van der Hoek; T W Kuijper; S L Reed; A H Rowley; S T Shulman; H K B Talbot; J V Williams; J C Burns
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

Review 6.  Detection of respiratory viruses by molecular methods.

Authors:  James B Mahony
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

7.  Coronavirus HKU1 infection in the United States.

Authors:  Frank Esper; Carla Weibel; David Ferguson; Marie L Landry; Jeffrey S Kahn
Journal:  Emerg Infect Dis       Date:  2006-05       Impact factor: 6.883

8.  CD40 Gene polymorphisms associated with susceptibility and coronary artery lesions of Kawasaki disease in the Taiwanese population.

Authors:  Ho-Chang Kuo; Mei-Chyn Chao; Yu-Wen Hsu; Ying-Chi Lin; Ying-Hsien Huang; Hong-Ren Yu; Ming-Feng Hou; Chi-Di Liang; Kuender D Yang; Wei-Chiao Chang; Chih-Lu Wang
Journal:  ScientificWorldJournal       Date:  2012-05-02

9.  Lack of association between CLEC5A gene single-nucleotide polymorphisms and Kawasaki disease in Taiwanese children.

Authors:  Ya-Ling Yang; Wei-Pin Chang; Yu-Wen Hsu; Wei-Chiao Chen; Hong-Ren Yu; Chi-Di Liang; Yao-Ting Tsai; Ying-Hsien Huang; Kuender D Yang; Ho-Chang Kuo; Wei-Chiao Chang
Journal:  J Biomed Biotechnol       Date:  2011-12-22

Review 10.  Skin manifestations of COVID-19 in children: Part 2.

Authors:  D Andina; A Belloni-Fortina; C Bodemer; E Bonifazi; A Chiriac; I Colmenero; A Diociaiuti; M El-Hachem; L Fertitta; D van Gysel; A Hernández-Martín; T Hubiche; C Luca; L Martos-Cabrera; A Maruani; F Mazzotta; A D Akkaya; M Casals; J Ferrando; R Grimalt; I Grozdev; V Kinsler; M A Morren; M Munisami; A Nanda; M P Novoa; H Ott; S Pasmans; C Salavastru; V Zawar; A Torrelo
Journal:  Clin Exp Dermatol       Date:  2020-11-09       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.